SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-008382
Filing Date
2023-05-08
Accepted
2023-05-08 07:30:48
Documents
69
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20230331x10q.htm   iXBRL 10-Q 1430377
2 EX-10.4 acrs-20230331xex10d4.htm EX-10.4 16591
3 EX-31.1 acrs-20230331xex31d1.htm EX-31.1 15615
4 EX-31.2 acrs-20230331xex31d2.htm EX-31.2 15655
5 EX-32.1 acrs-20230331xex32d1.htm EX-32.1 9510
  Complete submission text file 0001558370-23-008382.txt   6746109

Data Files

Seq Description Document Type Size
6 EX-101.SCH acrs-20230331.xsd EX-101.SCH 39879
7 EX-101.CAL acrs-20230331_cal.xml EX-101.CAL 45611
8 EX-101.DEF acrs-20230331_def.xml EX-101.DEF 189265
9 EX-101.LAB acrs-20230331_lab.xml EX-101.LAB 434159
10 EX-101.PRE acrs-20230331_pre.xml EX-101.PRE 300525
63 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20230331x10q_htm.xml XML 1295226
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 23895848
SIC: 2834 Pharmaceutical Preparations